HTA projects

All HTA projects in progress or completed are listed below. Published here in the course of each project are the protocol and the HTA report, together with the feedback received from stakeholders. The reports are written in English (with summaries in French, German and Italian).

20.10.2023

Benzodiazepines for anxiety disorders

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

20.10.2023

Thermoablation for benign thyroid nodules

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

20.10.2023

Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

20.10.2023

Physiotherapy for cervical spine syndrome

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

20.10.2023

Superficial/deep heat in physiotherapy for musculoskeletal conditions

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

20.10.2023

Bronchial thermoplasty for severe asthma

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

20.10.2023

Valerian extracts for sleep disorders, anxiety or restlessness

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

29.09.2023

Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee

Patients with knee and hip osteoarthritis may be treated with intra-articular glucocorticoid injections, which are publicly reimbursed in Switzerland. However, the efficacy of this treatment remains unclear. This HTA report aims to evaluate the safety, efficacy, costs, cost-effectiveness and budget impact of intra-articular glucocorticoid injections.

22.09.2023

Prevention of chronic and episodic migraine with CGRP antagonists

Various treatment options are available for prevention of chronic and episodic migraine. In addition to beta blockers, calcium antagonists and antidepressants, these include monoclonal antibodies known as CGRPs. The report concludes that the use of CGRP antagonists reduced the number of migraine days overall, and more than halved the number of migraine days and improved the quality of life of more people versus placebo and supportive measures in the control group. A reduction in the price of CGRP antagonists would significantly improve the cost-benefit ratio and thus reduce the impact on the cost budget.

15.08.2023

Comparison of surgical improvement of vascular blood flow with drug therapy in subjects with chronic cardiovascular disease

In addition to medication, surgical interventions to improve vascular blood flow are another means used to treat chronic cardiovascular disease. Surgeons will either perform heart bypass surgery or insert tubular vascular stents into the narrowed blood vessels. The report concludes that heart bypass surgery is superior to drug therapy alone. For tubular vascular stents, the benefit was less clear and only demonstrated in the short term.

28.07.2023

Treatment duration of Trastuzumab in early HER2-positive breast cancer

The drugs trastuzumab and pertuzumab are used in Switzerland to treat breast cancer if cancer cells overexpress the HER2 receptor. The approved treatment duration of trastuzumab is a maximum of 12 months and can be started before or after surgical removal of cancer cells. An HTA report was commissioned to evaluate the reimbursement requirement with the aim of reviewing the efficacy, safety, cost-effectiveness and budgetary impact.

23.06.2023

Folate tests for suspected folate deficiency

This HTA report examines the safety, the effectiveness, the costs and the cost-effectiveness of conducting folate tests on symptom-free persons and on persons for whom symptoms, medical problems or other factors suggest a possible folate deficiency. The report further examines ethical, social and organisational issues in connection with folate testing.

16.06.2023

CAR-T-cell therapies

The CAR T cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) are provisionally listed in Appendix 1 of the Health Insurance Benefits Ordinance, and are reimbursed by Swiss mandatory health insurance for the treatment of diffuse large B cell lymphoma (DLBCL; Kymriah® and Yescarta®), B cell acute lymphocytic leukaemia (ALL; Kymriah®) and primary mediastinal B cell lymphoma (PMBCL; Yescarta®). To inform future reimbursement decision an HTA will be conducted with the aim of evaluating the safety, efficacy/effectiveness, costs, cost-effectiveness and budget impact of tisagenlecleucel and axicabtagene ciloleucel separately in these indications. In addition, ethical, legal, social and organisational issues associated with these therapies will be investigated.

07.06.2023

Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Oral anticoagulants are administered to persons with atrial fibrillation to prevent strokes. As part of an HTA, the use of direct oral anticoagulants (DOACs) was compared to that of vitamin K antagonists (VKAs). Studies suggest that DOACs are slightly more effective than VKAs in total mortality terms. Improvements were observed in the prevention of bleeding, while the difference between the two types of anticoagulant was only minor in stroke prevention terms. While more expensive, DOACs showed a superior benefit-cost ratio compared to VKAs.

24.04.2023

Tumor treating fields (TTFields) for patients with glioblastoma

In Switzerland, tumour treating fields (TTFields) for the treatment of newly diagnosed glioblastoma are reimbursed through the statutory health insurance under certain circumstances. To evaluate the reimbursement obligation, a HTA was commissioned with the aim of investigating the efficacy, safety, cost-effectiveness and budgetary impact of TTFields for patients with glioblastoma. As well as the use of TTFields for newly diagnosed glioblastoma, the HTA also examines their use in recurring glioblastoma. The ethical, legal, organisational and social aspects of treatment with TTFields are also evaluated in the HTA report.

11.11.2022

Hormone tests in suspected thyroid dysfunction

Where thyroid dysfunction is suspected, testing for thyroid hormones may provide useful insights. Two test approaches exist: the one-step test measures thyroid-stimulating hormone (TSH) and other thyroid hormones in a single step, while the two-step approach measures just the TSH to begin with. The report concludes that, from a clinical perspective, using the two-step testing approach carries only a low risk of missing cases of thyroid dysfunction. In terms of costs, the two-step approach represented a cost saving compared with the one-step approach.

28.10.2022

Use of the hormone Levothyroxine to treat a slightly underactive thyroid gland

One sign of a slightly underactive thyroid gland is a raised level of the hormone which stimulates the thyroid – known as thyroid-stimulating hormone, or TSH. The hormone levels in the thyroid are still within the normal range at this stage and symptoms are only minimal. To treat this condition in Switzerland, a manufactured form of the body’s own thyroid hormone is used – the hormone Levothyroxine. The report concludes that treatment with Levothyroxine successfully reduces the level of the TSH hormone, but does not reduce the associated complaints or side effects.

21.10.2022

Medications against dementia in Alzheimer’s and Parkinson's disease

This HTA report investigates the efficacy of various anti-dementia medications for the treatment of dementia symptoms in Alzheimer’s and Parkinson's disease. Literature searches found that in mild to moderate and in some cases also in advanced dementia in Alzheimer’s and Parkinson's disease, the anti-dementia medications used had a certain positive effect, for example on cognitive abilities, compared to placebo. Considered over a longer period, the cost/benefit ratio for most of the anti-dementia medications was positive.

06.05.2022

Comparison of dosing schedules for drugs to treat bone metastases

Cancer sufferers with bone metastases receive drugs on a monthly basis to reduce the risk of fractures and the release of excess calcium into the bloodstream. The latest studies indicate that administering the drugs only every three months rather than every month is similarly effective but is associated with a lower risk of side effects. Comparing trimonthly to monthly dosing, the analyses only showed minimal differences in terms of potential side effects while the efficacy was the same. If doctors treated patients on a trimonthly dosing interval from the outset, this would result in potential savings of over CHF 53 million in the next five years.

06.05.2022

Denosumab (Prolia®) for the treatment of osteoporosis

Denosumab (Prolia®) is used to treat bone loss, particularly among women after the menopause and people who are at a higher risk of breaking bones or who are undergoing certain cancer treatments. In 2017 there were reports that stopping therapy with denosumab could lead to excessive counter-reactions such as loss of bone density and a greater risk of broken bones in the area of the spine. The report concludes that among most of the patient groups treated, denosumab achieved similar effects to other therapies and displayed a similar degree of safety.

09.02.2022

Sedative and sleep-promoting medicines for the treatment of chronic sleep disorders

The group of sedative and sleep-promoting medicines is used in sleep disorders in order to alleviate persistent episodes of tension and anxiety. According to the product information they should not be prescribed for longer than four weeks. According to the report, the evidence indicated that the drugs remain effective to a certain extent and are safe even during long-term use, but that they are not necessarily cost efficient. The use of sedative and sleep-promoting medicines leads to dependency and increasing doses.

07.12.2021

Multigene-expression tests for breast cancer

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

02.11.2021

Vitamin B12 tests

The use of vitamin B12 tests in Switzerland has risen sharply in recent years. The aim of the report was to identify the advantages and disadvantages of various vitamin B12 tests and establish whether tests are needed at all before dispensing vitamin B12. The report concludes that the existing findings do not indicate whether a vitamin B12 test or test combination should be used, and if so which ones, or whether the tests have any influence on the treatment.

16.09.2021

Magnesium supplements

This topic is currently in development. As soon as reports on this topic are available, they will be published here.

Examples for search terms:
osteoarthritis or osteo* or *arthritis 

Last modification 02.09.2022

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Are you interested in receiving regular updates from the Swiss HTA programme? If yes, please subscribe here to our newsletter!

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte.html